Press releases

28 December, 2018

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 December 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 126,235 as a result of ...

11 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 1 pm on Thursday 17 January 2019 at Medicon Village, Scheelevägen ...

11 December, 2018

Regulatory

Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”

Lund, Sweden, 11 December 2018 – NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018:

10 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

10 December, 2018

Regulatory

NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report

Lund, Sweden, 10 December 2018 - NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "t ...

10 December, 2018

Regulatory

Outcome of the Exercise of Warrants in NeuroVive

Lund, Sweden, 10 December 2018 –NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or “the Company”) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announces the outcome of the exercise of warrants of serie ...

22 November, 2018

Regulatory

NeuroVive Pharmaceutical AB Interim report January – September 2018

KL1333 approved for phase I clinical trial

15 November, 2018

Regulatory

NeuroVive receives Vinnova funding to support development of NV354, a novel treatment for genetic mitochondrial disorders

Lund, 15 November, 2018- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in ...

31 October, 2018

Regulatory

NeuroVive today announces that the subscription period for warrants of series 2018:1 will begin on Thursday, November 1

Lund, Sweden October 31 2018 – NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or ”the Company”) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces today that the subscription period for the warrants of ...

18 October, 2018

NeuroVive presents first preclinical NV354 efficacy results in a model for mitochondrial disease

Lund, Sweden, 18 October 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that positive experimental results for NV354, NeuroVive’s preclinical lead candidate i ...

10 October, 2018

Regulatory

NeuroVive receives KL1333 clinical trial regulatory approval

Lund, Sweden, 10 October 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned p ...

4 October, 2018

Regulatory

NeuroVive reports first NeuroSTAT clinical efficacy signal in TBI

Lund, Sweden, 4 October 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in se ...